BrECADD in three days: Implementation of a condensed intensive first‐line regimen in Hodgkin lymphoma
British Journal of Haematology · 2026-11 · 209 (5) · 2094-2102
DOI: 10.1111/bjh.70771 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 21.08.2026. Verfasst von Christian Peter Jaworek und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Faculty of Medicine and University Hosp…. Hauptthemen laut MEDLINE: Hodgkin Disease, Antineoplastic Combined Chemotherapy Protocols, Brentuximab Vedotin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Intensive multiagent treatment regimens have substantially improved outcomes in advanced‐stage classic Hodgkin lymphoma (cHL). Brentuximab vedotin (BV), etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (BrECADD) demonstrated the highest efficacy in cHL reported to date in a randomised phase III trial. Cytotoxic agents are conventionally administered during the first 4 days of a 21‐day cycle. A total of four cycles are applied to patients with a complete response after two cycles, otherwise six cycles. We developed a condensed BrECADD protocol, reducing intravenous administration days to only three (−25%). Between January 2024 and July 2026, 30 patients received 132 cycles of 3‐day BrECADD at our institution. Primary objective was to describe feasibility and safety; secondary objectives included response, progression‐free survival (PFS) and overall survival (OS). Grade ≥3 adverse events occurred in 23 patients (77%), predominantly haematological. Six patients (20%) had grade ≥3 infections (four viral, two bacterial) and six (20%) had pathogen‐unspecified febrile neutropenia. Twenty‐four patients (80%) required only four BrECADD cycles. There were no treatment discontinuations. After a median follow‐up of 18 months (range 4–29), 1‐year PFS and OS rates were both 100%. Based on these encouraging results, the condensed 3‐day protocol is considered feasible and we recommend it for future BrECADD use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
- German Hodgkin Study Group (GHSG), Cologne, Germany.
- MV Zentrum Hämatologie und Onkologie, Cologne, Germany.
- Faculty of Medicine and University Hospital Cologne, Institute of Transfusion Medicine, University of Cologne, Cologne, Germany.
- Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Ger…
- Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein Campus, Kiel, Germany.
ORCID-Profile: Christian Peter Jaworek, Maja Supprian, Paul Jan Bröckelmann, Hishan Tharmaseelan, Dennis A Eichenauer, Janina Jablonski, Jan-Michel Heger, Jon Rischewski, Jannik Stemler, Wolfram Klapper, Peter Borchmann, Bastian von Tresckow
Zitieren
APA
Jaworek, C. P., Supprian, M., Bröckelmann, P. J., Tharmaseelan, H., Ferdinandus, J., Eichenauer, D. A., Robertz, A. S., Jablonski, J., Combüchen, V., Staak, J. O., Töpelt, K., Heger, J. M., Rischewski, J., Stemler, J., Klapper, W., Borchmann, P., & von Tresckow, B. (2026). BrECADD in three days: Implementation of a condensed intensive first‐line regimen in Hodgkin lymphoma. British Journal of Haematology, 209(5), 2094-2102. https://doi.org/10.1111/bjh.70771
Vancouver
Jaworek CP, Supprian M, Bröckelmann PJ, Tharmaseelan H, Ferdinandus J, Eichenauer DA, et al. BrECADD in three days: Implementation of a condensed intensive first‐line regimen in Hodgkin lymphoma. British Journal of Haematology. 2026;209(5):2094-2102. doi:10.1111/bjh.70771
BibTeX
@article{Jaworek2026,
author = {Jaworek, Christian Peter and Supprian, Maja and Bröckelmann, Paul Jan and Tharmaseelan, Hishan and Ferdinandus, Justin and Eichenauer, Dennis A and Robertz, Anne Sophie and Jablonski, Janina and Combüchen, Vincent and Staak, Jan-Oliver and Töpelt, Karin and Heger, Jan-Michel and Rischewski, Jon and Stemler, Jannik and Klapper, Wolfram and Borchmann, Peter and von Tresckow, Bastian},
title = {BrECADD in three days: Implementation of a condensed intensive first‐line regimen in Hodgkin lymphoma},
journal = {British Journal of Haematology},
year = {2026},
volume = {209},
number = {5},
pages = {2094--2102},
doi = {10.1111/bjh.70771}
}
EUVIMED